If the host’s immune status may be well maintained and tumor cells are scarce, the treatment strategies aiming for a cure with CDK4/6 inhibitors or immune-related agents [9], rather than cytotoxic agents, should be considered an option. This evidence concerns the gene CDK4 and neoplasm.